Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MPI | P34949 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6740032 | 1.00 | NTRK1 (0.54) | NTRK1MAPTKDM4ELMNAGAA | |
| SCHEMBL16224328 | 0.86 | NTRK1 (0.56) | NTRK1MAPT | |
| SCHEMBL6744652 | 0.85 | GAA (0.71) | NTRK1MAPTKDM4ELMNAGAA | |
| SCHEMBL6744649 | 0.85 | GAA (0.71) | NTRK1MAPTKDM4ELMNAGAA | |
| Hydrochloric Acid SCHEMBL17560777 | 0.84 | NTRK1 (0.55) | NTRK1MAPT | |
| Hydrochloric Acid SCHEMBL6843997 | 0.83 | GAA (0.69) | NTRK1MAPTKDM4ELMNAGAA | |
| Hydrochloric Acid SCHEMBL6843998 | 0.83 | GAA (0.69) | NTRK1MAPTKDM4ELMNAGAA | |
| SCHEMBL20013929 | 0.83 | GAA (0.73) | NTRK1MAPTKDM4ELMNAGAA | |
| SCHEMBL19996098 | 0.83 | GAA (0.73) | NTRK1MAPTKDM4ELMNAGAA | |
| SCHEMBL13673535 | 0.81 | NTRK1 (0.52) | NTRK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030186993-A1 | Anti-malarial compounds, compositions and methods | KENNETH S. WARREN INSTITUTE | 2003-10-02 | — | — | US | claimed |
| WO-2001025192-A1 | GUANIDINE DERIVATIVES AND THEIR USE IN THE PRODUCTION OF A MEDICAMENT FOR BLOCKING XANTHINE OXIDASE/DEHYDROGENASE | MELACURE THERAPEUTICS AB (SE) | 2001-04-12 | — | — | WO | claimed |
| US-6689777-B2 | DEPOLYMERIZING HEMOZOIN USING 2-IMINO-NAPHTHO(1,2-D)THIAZOL-5-OL DERIVATIVES | KENNETH S. WARREN INSTITUTE | 2004-02-10 | — | — | US | disclosed |
| US-20030186993-A1 | Anti-malarial compounds, compositions and methods | KENNETH S. WARREN INSTITUTE | 2003-10-02 | — | — | US | disclosed |
| WO-2001025192-A1 | GUANIDINE DERIVATIVES AND THEIR USE IN THE PRODUCTION OF A MEDICAMENT FOR BLOCKING XANTHINE OXIDASE/DEHYDROGENASE | MELACURE THERAPEUTICS AB (SE) | 2001-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186993-A1 | Anti-malarial compounds, compositions and methods | TYR, CRYZ, RHOT2 | NTRK1 4882/4885MAPT 309/4885KDM4E 1240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.